Skip to main content

Dr. Julie A. Barta, MD

Pulmonology (Pulmonary Disease Physician)

  • Medicare participating

At a glance

Years since graduation
18
In the NPI registry since
2011
Medicare patients seen, 2024
267

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2008Medical school: Jefferson Medical College of Thomas Jefferson University
  • 2011Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pulmonary Disease Physician primary
    PA license MD454548
  • Critical Care Medicine (Internal Medicine) Physician
    PA license MD454548
  • Internal Medicine Physician
    PA license MD454548

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pulmonology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
267
Services billed
578
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes9274
Established patient office or other outpatient visit, 40-54 minutes7962
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes6540
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes5329
New patient office or other outpatient visit, 60-74 minutes3333
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes2020
Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making)1818
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes1717
New patient office or other outpatient visit, 45-59 minutes1515
Established patient office or other outpatient visit, 20-29 minutes1414

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 1 payments worth $1,343 in total to this clinician.

By type
Consulting Fee$1,343

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Mar 2, 2025AstraZeneca Pharmaceuticals LP
Mar 2, 2025
Consulting Fee$1,343

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Pennsylvania →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $407,050 in research payments for these studies, mostly to the institutions running them.

  • Leveraging lung cancer screening to optimise clinical trial screening outcomes and COPD management
    AstraZeneca UK Limited
  • Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD
    AstraZeneca UK Limited
  • A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pulmonology clinicians in Philadelphia

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 17, 2015), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1376825281. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.